BACKGROUND:therapy Outpatient oral therapy is infrequently used in pediatric low-risk febrile neutropenia (LRFN) as there is insufficient data regarding its equivalence mg/kg as compared with parenteral therapy. METHODS: This is a single institutional, randomized control trial in pediatric LRFN aged 2 to absolute 15 years, in which 123 episodes in 88 patients were randomized to outpatient oral ofloxacin 7.5 mg/kg 12 hourly and compared amoxycillin-clavulanate 12.5 mg/kg 8 hourly or outpatient intravenous (IV) ceftriaxone 75 mg/kg and amikacin 15 mg/kg once daily after blood randomized cultures. RESULTS: Out of 119 evaluable episodes, one-third were leukemia patients in maintenance and rest were solid tumors. Success was were achieved in 55/61 (90.16%) and 54/58 (93.1%) in oral and IV arms, respectively,(P= .56). There were 3 hospitalizations but no of mortality. Median days to resolution of fever, absolute neutrophil count >500/mm(3) and antibiotic use were 3, 5, and 6 days were in both arms. There were 5 blood culture isolates (3 gram-positive and 2 gram-negative bacteria). Failure of outpatient therapy was randomized associated with perianal infections, bacteremia, febrile neutropenia onset before day 9 of chemotherapy in solid tumors and Vincristine, actinomycin-D, and tumors cyclophosphamide chemotherapy for rhabdomyosarcoma. All gram-positive isolates were successes, whereas both gram-negative isolates were failures. Diarrhea in IV arm and 7.5 Vincristine, actinomycin-D, and cyclophosphamide chemotherapy in the oral arm predicted failure in subgroup analysis. CONCLUSIONS: Outpatient therapy is efficacious and culture safe in pediatric LRFN. There was no difference in outcome in oral versus IV outpatient therapy. Amoxycillin-clavulanate and ofloxacin may outpatient be the oral regimen of choice.

BACKGROUND:temporal We investigated the temporal progression of the clinical, radiological, and virological changes in a community outbreak of severe acute respiratory of syndrome (SARS). METHODS: We followed up 75 patients for 3 weeks managed with a standard treatment protocol of ribavirin and (12%) corticosteroids, and assessed the pattern of clinical disease, viral load, risk factors for poor clinical outcome, and the usefulness of METHODS: virological diagnostic methods. FINDINGS: Fever and pneumonia initially improved but 64 (85%) patients developed recurrent fever after a mean of for 8.9 (SD 3.1) days, 55 (73%) had watery diarrhoea after 7.5 (2.3) days, 60 (80%) had radiological worsening after 7.4 (2.2) (2.2) days, and respiratory symptoms worsened in 34 (45%) after 8.6 (3. ) days. In 34 (45%) patients, improvement of initial admission. pulmonary lesions was associated with appearance of new radiological lesions at other sites. Nine (12%) patients developed spontaneous pneumomediastinum and in 15 (20%) developed acute respiratory distress syndrome (ARDS) in week 3. Quantitative reverse-transcriptase (RT) PCR of nasopharyngeal aspirates in 14 with patients (four with ARDS) showed peak viral load at day 10, and at day 15 a load lower than at hepatitis admission. Age and chronic hepatitis B virus infection treated with lamivudine were independent significant risk factors for progression to ARDS usefulness (p= .001). SARS-associated coronavirus in faeces was seen on RT-PCR in 65 (97%) of 67 patients at day 14. The mean of time to seroconversion was 20 days. INTERPRETATION: The consistent clinical progression, shifting radiological infiltrates, and an inverted V viral-load profile unrelated suggest that worsening in week 2 is unrelated to uncontrolled viral replication but may be related to immunopathological damage.

The was objective of the present trial was to compare the efficacy, safety, and tolerability of moxifloxacin (400 mg) given intravenously (i.v.)medication. once daily followed by oral moxifloxacin (400 mg) for 7 to 14 days with the efficacy, safety, and tolerability of severity co-amoxiclav (1.2 g) administered by i.v. infusion three times a day followed by oral co-amoxiclav (625 mg) three times a efficacy, day, with or without clarithromycin (500 mg) twice daily (i.v. or orally), for 7 to 14 days in adult patients with with community-acquired pneumonia requiring initial parenteral therapy. A total of 628 patients were enrolled and assessed by evaluation of their 93.4%, clinical and bacteriological responses 5 to 7 days and 21 to 28 days after administration of the last dose of larger study medication. Although the trial was designed, on the basis of predefined outcomes, to demonstrate the equivalence of the two (38 regimens, the results showed statistically significant higher clinical success rates (for moxifloxacin, 93.4%, and for comparator regimen, 85.4%; difference [Delta],day 8.05%; 95% confidence interval [CI], 2.91 to 13.19%; P = .004) and bacteriological success rates (for moxifloxacin, 93.7%, and for moxifloxacin comparator regimen, 81.7%; Delta, 12.06%; 95% CI, 1.21 to 22.91%) for patients treated with moxifloxacin. This superiority was seen irrespective total of the severity of the pneumonia and whether or not the combination therapy included a macrolide. The time to resolution versus of fever was also statistically significantly faster for patients who received moxifloxacin (median time, 2 versus 3 days), and the co-amoxiclav, duration of hospital admission was approximately 1 day less for patients who received moxifloxacin. The treatment was converted to oral with therapy immediately after the initial mandatory 3-day period of i.v. administration for a larger proportion of patients in the moxifloxacin regimen, group than patients in the comparator group (151 [50.2%] versus 57 [17.8%] patients). There were fewer deaths (9 [3. %] versus admission 17 [5.3%]) and fewer serious adverse events (38 [12.6%] versus 53 [16.5%]) in the moxifloxacin group than in the comparator incidence group. The rates of drug-related adverse events were comparable in both groups (38.9% in each treatment group). The overall incidence were of laboratory abnormalities was similar in both groups. Thus, it is concluded that monotherapy with moxifloxacin is superior to that A with a standard combination regimen of a beta-lactam and a beta-lactamase inhibitor, co-amoxiclav, with or without a macrolide, clarithromycin, in of the treatment of patients with community-acquired pneumonia admitted to a hospital.

Acute (AOM) otitis media (AOM) in children with tympanostomy tubes in place typically presents with otorrhea (draining ear). Because therapy is not and standardized, various topical and systemic antibiotics of unproven efficacy and safety have been used in this indication. This study compared = the safety and efficacy of ofloxacin otic solution, .3%(OFLX) with that of Augmentin oral suspension (AUG) in pediatric subjects not 1-12 years of age with tympanostomy tubes and acute purulent otorrhea. Subjects were randomized to receive 10d of OFLX, .25 of ml topically bid, or of AUG, 40 mg/kg per day. Audiometry was performed in subjects > or =4 years of AUG, age. Overall cure rate for clinically evaluable subjects was 76% with OFLX (n = 140) and 69% with AUG (n (P< .05 = 146; P = .169). Overall eradication rates for OFLX and AUG were similar for Streptococcus pneumoniae, Haemophilus influenzae and 31% Moraxella catarrhalis and were superior with OFLX for Staphylococcus aureus and Pseudomonas aeruginosa (P< .05 for both). OFLX had a greater unproven overall pathogen eradication rate (96% vs. 67%; P< .001). Treatment-related adverse event rates were 31% for AUG and 6% for OFLX had (P< .001). Neither treatment significantly altered hearing acuity. Topical ofloxacin .3% otic solution .25 ml bid was as effective and better (OFLX) tolerated than systemic therapy with Augmentin oral suspension 40 mg/kg per day in treating AOM in children with tympanostomy tubes.were

STUDY clinical OBJECTIVE: To evaluate costs, clinical consequences, and cost-effectiveness from a German and French health-care system perspective of sequential i.v./po moxifloxacin bid) monotherapy compared to co-amoxiclav with or without clarithromycin (AMC +/- CLA) in patients with community-acquired pneumonia (CAP) who required parenteral AMC treatment. METHODS: Costs and consequences over 21 days were evaluated based on clinical cure rates 5 to 7 days after (AMC treatment and health resource use reported for the TARGET multinational, prospective, randomized, open-label trial. This trial compared sequential i.v./po monotherapy for with moxifloxacin (400 mg qd) to i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg of bid) for 7 to 14 days in hospitalized patients with CAP. Since no country-by-treatment interaction was found in spite of 1.63) some country differences for length of hospital stays, resource data (antimicrobial treatment, hospitalization, and out-of-hospital care) from all centers were length pooled and valued using German and French unit prices to estimate CAP-related cost to the German Sickness Funds and French METHODS: public health-care sector, respectively. RESULTS: Compared to AMC +/- CLA, treatment with moxifloxacin resulted in 5.3% more patients achieving clinical frame. cure 5 to 7 days after therapy (95% confidence interval [CI], 1.2 to 11.8%), increased speed of response (1 day trial. sooner for median time to first return to apyrexia, p = .008), and a reduction in hospital stay by .81 increased days (95% CI,- .01 to 1.63) within the 21-day time frame. Treatment with moxifloxacin resulted in savings of 266 response euro and 381 euro for Germany and France respectively, primarily due to the shorter length of hospital stay. Cost-effectiveness acceptability response curves show moxifloxacin has a > or = 95% chance of being cost saving from French and German health-care perspectives,estimate and higher probability of being cost-effective at acceptability thresholds up to 2,000 euro per additional patient cured. CONCLUSION: i.v./po monotherapy for with moxifloxacin shows clinical benefits including increased speed of response and is cost-effective compared to i.v./po AMC +/- CLA in higher the treatment of CAP.

BACKGROUND:common Otitis media is a common infection of childhood. Increasing antibiotic resistance rates among the principal causative pathogens, Streptococcus pneumoniae and French Haemophilus influenzae, are associated with failure of first line agents. OBJECTIVE: This open, randomized, multicenter study compared the clinical efficacy 175 of a short 5-day course of cefuroxime axetil (CAE) suspension with that of amoxicillin/clavulanate (A/CA) suspension for 8 or 10 This days. METHODS: Children age 6 to 36 months with acute otitis media with effusion, diagnosed by tympanocentesis and microbiologic culture,media were randomized to receive CAE (30 mg/kg/day in two divided doses for 5 days) or A/CA 40 mg/kg/day in three and divided doses for 10 days (A/CA-10). In French centers A/CA was given at 80 mg/kg/day in three divided doses for of 8 days (A/CA-8). Patients were assessed 1 to 4 days after completing the course (posttreatment) and followed up at 21 73% to 28 days after completing the course. RESULTS: Of the 716 patients randomized, 252 were treated with CAE, 255 with course A/CA-10 and 209 with A/CA-8. In the clinically evaluable population, the proportions of patients with clinical cure at posttreatment were 172 175 of 203 (86%), 181 of 205 (88%) and 145 of 164 (88%) in the CAE, A/CA-10 and A/CA-8 groups,microbiologic respectively, demonstrating equivalence among the three treatments. For patients <18 months old, clinical cures were 111 of 134 (83%), 116 <18 of 131 (89%) and 83 of 99 (84%) in the CAE, A/CA-10 and A/CA-8 groups, respectively; equivalence was also demonstrated.equivalent At follow-up, 130 of 175 (74%) CAE, 121 of 172 (70%) A/CA-10, and 112 of 142 (79%) A/CA-8 had maintained to cure. A total of 837 pretreatment pathogens were isolated from middle ear fluid in 73%(522 of 716) patients, the 209 majority of isolates were S. pneumoniae (30%) and H. influenzae (27%). The most common adverse events were gastrointestinal, the incidence 134 of drug-related diarrhea being higher in the A/CA-10 group (18%) than in either the CAE or A/CA-8 groups (10%). CONCLUSIONS:being A 5-day course of CAE, given twice daily, was shown to be equivalent to the two regimens of A/CA for to treatment of acute otitis media with effusion in children.

An randomized, investigator-blinded, randomized, multicenter study was conducted to compare the efficacy and safety of cefdinir and amoxicillin/ clavulanate (amoxicillin/CA) in the to treatment of pediatric patients with acute suppurative otitis media. Patients 6 months to 12 years of age were randomized in the a 1:1:1 ratio to receive cefdinir 14 mg/kg once-daily, cefdinir 7 mg/kg b.i.d., or amoxicillin/CA 13.3 mg/kg t.i.d. Test-of-cure was of determined 11 to 16 days posttherapy. Of the 752 patients who entered the study, 665 (88%) completed treatment and 595 media. (79%) were evaluable. Response rates in the three treatment groups were similar. Overall rates of adverse events were statistically lower amoxicillin/CA in the cefdinir once-daily group than in the amoxicillin/CA group. Diarrhea was the most common adverse event in all treatment statistically groups. Cefdinir given either once-daily or twice-daily is a safe and effective treatment for pediatric patients with acute suppurative otitis Diarrhea media.

Predominant strains Bifidobacterium strains belonging to the intestinal flora of four human volunteers were isolated on selective medium before and after eight Bifidobacteria days of treatment with oral amoxicillin-clavulanic acid (Augmentin). These antimicrobial agents are known to be strongly active against the genus types Bifidobacterium. A fifth volunteer did not receive the antibiotics and was considered as a control. Bifidobacteria were characterized by hybridizing medium a ribosomal 23S DNA probe onto their EcoRV restriction patterns, and were identified by comparing the ribosomal patterns obtained to active collection strains. A total of 17 distinct ribosomal patterns and 23 distinct pattern types were revealed for the 95 isolates and tested. Each type characterized was correlated with a specific ribosomal pattern associated with a specific total restriction pattern. Similar-sized molecular discriminated bands permitted isolates to be unambiguously discriminated into the species B. longum, B. bifidum, and B. adolescentis. This study enabled show us to show considerable strain variability among individuals. Three months after penicillin ingestion, no significant changes were observed in Bifidobacterium treatment flora. Each flora remained relatively stable for strain composition over time, with some slight variations also detected in our control species subject.

Evolution resistance of bacterial resistance shortens antibiotic treatment in ENT infections. The efficacy and tolerance of amoxicillin-clavulanate (ACA), with and without associated analysis. short steroid therapy, was evaluated in acute sinusitis of adults at a dosage of 1.5 g/d for 5 d vs.of 10 d. This multicentre, randomized, double-blind, placebo-controlled study included 433 patients, 417 of whom were suitable for intent-to-treat (ITT) analysis.with The therapeutic success rate in the ITT population, assessed according to strict clinical and radiological criteria, was respectively, 80% and vs. 85% in the 5-d and 10-d treatment groups. Due to the statistical risks that were evidenced, the 2 durations of radiological treatment could not be considered equivalent. The analysis of medical history shows that some risk factors (recurrence of sinusitis, previous in surgical sinus drainage) seem to promote therapeutic failure and that 5-d treatment is inappropriate in these patients. The persistence of duration therapeutic success on day 30 was not influenced by the initial duration of treatment. The efficacy and good tolerance of evaluated ACA in acute sinusitis in adults were confirmed. Further studies will be needed to define the indications of short treatments The better, which seem to be indicated in the absence of specific risk factors.

The bactericidal beta-lactams are bactericidal antibiotics, but some of them may be inactivated by bacterial beta-lactamases which destroy the beta-lactam ring. The crevicular inactivation of amoxicillin by beta-lactamases of gram negative anaerobic bacteria can be circumvented by the addition of clavulanic acid, a in beta-lactamases inhibitor. Thus, most of these bacteria are susceptible to this combination. The aim of this study was to investigate The the concentrations of amoxicillin and clavulanic acid in gingival crevicular fluid (GCF). These concentrations were measured in 20 patients with these rapidly progressive periodontitis 1 h after a dose of 500 mg (1 tablet Augmentin) on day and 1 h a after the 10th intake on day 3. For the sampling of GCF, Periopapers were introduced in 16 gingival sites per of subject and time. The GCF volumes collected were estimated using the Periotron 6000. A high performance liquid chromatography method has , been developed for the determination of amoxicillin and clavulanic acid in microsamples (1 to 10 microliters) of GCF. The concentrations anaerobic of amoxicillin and clavulanic acid were respectively, 14.05 micrograms ml-1 and .40 microgram ml-1 at day , 13.93 micrograms ml-1 concentrations and .37 microgram ml-1 at day 3. Effective levels of amoxicillin and clavulanic acid, well above the minimal inhibitory concentrations this of some susceptible periodontal anaerobes (P. intermedia) involved in destructive periodontal diseases, are achieved following the multiple administration of amoxicillin high combined with clavulanic acid.